Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT). CSCs have been observed in...

Full description

Bibliographic Details
Main Authors: Sylvia M. Cruz, Khurshid R. Iranpur, Sean J. Judge, Erik Ames, Ian R. Sturgill, Lauren E. Farley, Morgan A. Darrow, Jiwon Sarah Crowley, Arta M. Monjazeb, William J. Murphy, Robert J. Canter
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:International Journal of Molecular Sciences
Subjects:
cancer stem cells
sorafenib
ALDH
sarcoma
survival
Online Access:https://www.mdpi.com/1422-0067/25/6/3351

Internet

https://www.mdpi.com/1422-0067/25/6/3351

Similar Items